| Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States AR Mato, M Thompson, JN Allan, DM Brander, JM Pagel, CS Ujjani, ... Haematologica 103 (9), 1511, 2018 | 179 | 2018 |
| Atrial myxoma: a case presentation and review R Cohen, G Singh, D Mena, CA Garcia, P Loarte, B Mirrer Cardiology Research 3 (1), 41, 2012 | 58 | 2012 |
| Neurologic immune-related adverse events associated with adjuvant ipilimumab: report of two cases CA Garcia, A El-Ali, TJ Rath, LC Contis, V Gorantla, J Drappatz, D Davar Journal for immunotherapy of cancer 6, 1-6, 2018 | 44 | 2018 |
| Cavernous transformation of portal vein secondary to portal vein thrombosis: a case report R Ramos, Y Park, G Shazad, C AGarcia, R Cohen Journal of Clinical Medicine Research 4 (1), 81, 2012 | 27 | 2012 |
| Heparin induced thrombocytopenia: case presentation and review RA Cohen, M Castellano, CA Garcia Journal of Clinical Medicine Research 4 (1), 68, 2012 | 24 | 2012 |
| Attributable risk of infection to mTOR inhibitors everolimus and temsirolimus in the treatment of cancer CA Garcia, S Wu Cancer Investigation 34 (10), 521-530, 2016 | 23 | 2016 |
| Diagnosis of immune thrombocytopenia, including secondary forms, and selection of second-line treatment JB Bussel, CA Garcia Haematologica 107 (9), 2018, 2022 | 14 | 2022 |
| Electrocardiogram manifestations in hyperkalemia R Cohen, R Ramos, CA Garcia, S Mehmood, Y Park, A Divittis, B Mirrer World Journal of Cardiovascular Diseases 2 (2), 57-63, 2012 | 13 | 2012 |
| Discontinuation of everolimus due to related and unrelated adverse events in cancer patients: a meta-analysis SC Rogers, CA Garcia, S Wu Cancer Investigation 35 (8), 552-561, 2017 | 6 | 2017 |
| Syncope as initial presentation of Kommerell diverticulum R Cohen, P Loarte, C Garcia, L Diaz, B Mirrer International Journal of Angiology 21 (02), 111-116, 2012 | 5 | 2012 |
| Case review: idiopathic thrombocytopenic purpura R Cohen, CA Garcia, D Mena, M Castellanos Journal of Medical Cases 3 (2), 130-134, 2012 | 5 | 2012 |
| Disease Response with the Addition of Platinum-Based Chemotherapy to Pembrolizumab after Progression on Pembrolizumab Monotherapy in PD-L1–Expressing Non–Small Cell Lung Cancer CA Garcia, S Dacic, LC Villaruz Journal of Thoracic Oncology 13 (8), e135-e136, 2018 | 3 | 2018 |
| Top Ten Tips Palliative Care Clinicians Should Know About Caring for Filipino American and Korean American Patients JE Chung, S Karass, Y Choi, M Castillo, CA Garcia, RD Shin, K Tanco, ... Journal of palliative medicine 27 (1), 104-111, 2024 | 2 | 2024 |
| ITP: diagnosis including secondary ITP, and selection of second line treatment JB Bussel, C Garcia Haematologica, 2022 | 2 | 2022 |
| Risk of serious infection with mTOR inhibitors everolimus and temsirolimus in the treatment of cancer: A meta-analysis of randomized controlled trials. CA Garcia, S Wu Journal of Clinical Oncology 32 (15_suppl), 2604-2604, 2014 | 2 | 2014 |
| Comparative efficacy and safety of lorlatinib versus alectinib and lorlatinib versus brigatinib for ALK-positive advanced/metastatic NSCLC: matching-adjusted indirect comparisons C Garcia, D Abrahami, A Polli, H Chu, C Chandler, M Tan, JM Kelton, ... Clinical Lung Cancer 25 (7), 634-642, 2024 | 1 | 2024 |
| Integrating health equity in the ASCO guideline agenda: recommendations from members of the Palliative Care Expert Panel WE Rosa, CA Garcia, MA Mardones, S Temin, JJ Sanders JCO Oncology Practice 20 (10), 1300-1303, 2024 | 1 | 2024 |
| Discontinuation of everolimus due to unrelated adverse events in cancer patients. SC Rogers, CA Garcia, S Wu Journal of Clinical Oncology 34 (15_suppl), e14020-e14020, 2016 | 1 | 2016 |
| Comparative Efficacy and Safety of Lorlatinib vs. Alectinib and Lorlatinib vs. Brigatinib for AlLK-Positive Advanced/Metastatic NSCLC: Matching-Adjusted Indirect Comparisons C Garcia, D Abrahami, A Polli, H Chu, C Chandler, M Tan, JM Kelton, ... Alectinib and Lorlatinib vs. Brigatinib for AlLK-Positive Advanced …, 0 | 1 | |
| Assessing outcomes for patients receiving chemotherapy in the intensive care unit. AN Holmes, C Ippoliti, B Hayward, L Lief, D Berlin, CA Garcia JCO Oncology Practice 20 (10_suppl), 190-190, 2024 | | 2024 |
